SAGE-547
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Postpartum Depression
Conditions
Postpartum Depression
Trial Timeline
Jan 7, 2015 → Jun 5, 2015
NCT ID
NCT02285504About SAGE-547
SAGE-547 is a phase 2 stage product being developed by Supernus Pharmaceuticals for Postpartum Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT02285504. Target conditions include Postpartum Depression.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02433314 | Pre-clinical | Completed |
| NCT02285504 | Phase 2 | Completed |
| NCT02052739 | Phase 1/2 | Completed |
Competing Products
20 competing products in Postpartum Depression
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Misoprostol + Oxytocin | Cipla | Phase 3 | 77 |
| Quetiapine | AstraZeneca | Phase 2 | 52 |
| Azithromycin + Azithromycin and amoxicillin + Placebo | Merck | Approved | 85 |
| Eptacog alfa (NovoSeven) | Novo Nordisk | Approved | 84 |
| Eptacog alfa (activated) | Novo Nordisk | Pre-clinical | 22 |
| aripiprazole | Bristol Myers Squibb | Phase 3 | 76 |
| fibrinogen concentrate + Placebo | CSL | Phase 1/2 | 40 |
| SAGE-217 15/20 mg Oral Solution + Placebo + SAGE 217 30 mg Capsules | Biogen | Phase 3 | 74 |
| SAGE-217 + Placebo | Biogen | Phase 3 | 74 |
| Zuranolone | Biogen | Pre-clinical | 20 |
| Zuranolone | Biogen | Pre-clinical | 20 |
| LPCN 1154A + Placebo | Lipocine | Phase 3 | 69 |
| Goserelin 3.6 mg implant + Placebo | Brain Biotech | Pre-clinical | 15 |
| ZULRESSO (brexanolone) injection | Supernus Pharmaceuticals | Pre-clinical | 18 |
| Placebo + SAGE-547 90 μg/kg/h | Supernus Pharmaceuticals | Phase 3 | 72 |
| ZULRESSO® | Supernus Pharmaceuticals | Approved | 80 |
| Placebo + SAGE-547 60 μg/kg/h + SAGE-547 90 μg/kg/h | Supernus Pharmaceuticals | Phase 3 | 72 |
| SAGE-547 + Placebo | Supernus Pharmaceuticals | Phase 2 | 47 |
| GH001 | GH Research | Phase 2 | 47 |
| Brexanolone | Brain Biotech | Pre-clinical | 15 |